# Release of Bioactive Peptides from Whey Protein During In Vitro Digestion and Their Effect on CCK Secretion in Enteroendocrine Cells: An In Silico and In Vitro Approach

**Authors:** Anaís Ignot-Gutiérrez, Orlando Arellano-Castillo, Gloricel Serena-Romero, Mayvi Alvarado-Olivarez, Daniel Guajardo-Flores, Armando J. Martínez, Elvia Cruz-Huerta

PMC · DOI: 10.3390/molecules31020238 · 2026-01-10

## TL;DR

Whey protein digestion produces small peptides that boost CCK hormone release, which may help with satiety and metabolic health.

## Contribution

Integration of in vitro digestion, peptidomics, and in silico prediction to identify bioactive peptides from whey protein.

## Key findings

- Low-molecular-weight peptides from whey protein strongly stimulate CCK secretion in enteroendocrine cells.
- Peptides from β-lactoglobulin and α-lactalbumin show multiple bioactivities, including antihypertensive and antioxidant properties.
- The ENSAEPE motif in β-lactoglobulin is linked to neuropeptide-like activity.

## Abstract

During gastrointestinal digestion, dietary proteins are hydrolyzed into peptides and free amino acids that modulate enteroendocrine function and satiety-related hormone secretion along the gut–brain axis, thereby contributing to obesity prevention. We investigated whey protein concentrate (WPC) as a source of bioactive peptides and evaluated the effects of its digests on cholecystokinin (CCK) secretion in STC-1 enteroendocrine cells by integrating the standardized INFOGEST in vitro digestion protocol, peptidomics (LC–MS/MS), and in silico bioactivity prediction. In STC-1 cells, the <3 kDa intestinal peptide fraction exhibited the strongest CCK stimulation, positioning these low-molecular-weight peptides as promising bioactive components for satiety modulation and metabolic health applications. Peptidomic analysis of this fraction identified short sequences derived primarily from β-lactoglobulin (β-La) and α-lactalbumin (α-La), enriched in hydrophobic and aromatic residues, including neuropeptide-like sequences containing the Glu–Asn–Ser–Ala–Glu–Pro–Glu (ENSAEPE) motif of β-La f(108–114). In silico bioactivity profiling with MultiPep predicted antihypertensive, angiotensin-converting enzyme (ACE)–inhibitory, antidiabetic, dipeptidyl peptidase-IV (DPP-IV)–inhibitory, antioxidant, antibacterial, and neuropeptide-like activities. Overall, digestion of WPC released low-molecular-weight peptides and amino acids that enhanced CCK secretion in vitro; these findings support their potential use in nutritional strategies to enhance satiety, modulate appetite and energy intake, and improving cardiometabolic health.

## Linked entities

- **Chemicals:** angiotensin-converting enzyme (PubChem CID 37056)

## Full-text entities

- **Genes:** LALBA (lactalbumin alpha) [NCBI Gene 3906] {aka HAMLET, LYZG}, CCK (cholecystokinin) [NCBI Gene 885], DPP4 (dipeptidyl peptidase 4) [NCBI Gene 1803] {aka ADABP, ADCP2, CD26, DPPIV, TP103}, ACE (angiotensin I converting enzyme) [NCBI Gene 1636] {aka ACE1, CD143, DCP, DCP1}
- **Diseases:** obesity (MESH:D009765)

## Figures

6 figures with captions in the complete paper: https://tomesphere.com/paper/PMC12844283/full.md

---
Source: https://tomesphere.com/paper/PMC12844283